HK Stock Market Move | MAO GEPING (01318) rose more than 9%, with a year-on-year net profit growth of 36.73%. The growth rate of cosmetics and skin care exceeded 30%.
Maanshan Iron & Steel (01318) rose more than 9%, as of the time of drafting, it rose 8.97% to HK $75.9, with a trading volume of 1.01 billion Hong Kong dollars.
MAO GEPING (01318) rose more than 9%, as of the time of writing, the increase was 8.97%, at HK$75.9, with a trading volume of HK$1.01 billion.
On the news front, MAO GEPING announced its 2025 annual performance. The group achieved revenue of RMB 5.05 billion, an increase of 30.01% year-on-year. The profit attributable to the owners of the parent company was RMB 1.204 billion, an increase of 36.73% year-on-year, with earnings per share of RMB 2.46, and a proposed final dividend of RMB 1.00 per share.
It is worth mentioning that the company's two core business segments - cosmetics and skincare, both recorded growth rates of over 30% year-on-year. Among them, cosmetic revenue was RMB 2.996 billion, and skincare revenue was RMB 1.873 billion. In addition, the rise of the fragrance category was the highlight of the company's 2025 financial report, marking the company's successful breakthrough of the original product ceiling and starting a "third growth curve".
Related Articles

ZHOU HEI YA (01458) has been issuing generous dividends to shareholders for three consecutive years, further increasing dividend payments and initiating a new round of share buybacks.

Throughout the year, ZIBUYU (02420) has continued to achieve record highs in performance, unleashing strong growth potential through "brand building."

HK Stock Market Move | CSTONE PHARMA-B(02616) surged by more than 20%, CS2009 lung cancer efficacy data impressive, may initiate first phase III MRCT this year.
ZHOU HEI YA (01458) has been issuing generous dividends to shareholders for three consecutive years, further increasing dividend payments and initiating a new round of share buybacks.

Throughout the year, ZIBUYU (02420) has continued to achieve record highs in performance, unleashing strong growth potential through "brand building."

HK Stock Market Move | CSTONE PHARMA-B(02616) surged by more than 20%, CS2009 lung cancer efficacy data impressive, may initiate first phase III MRCT this year.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


